R. Wallis

发表

Integrated risk assessment and predictive value to humans of non‐clinical repolarization assays

R. Wallis, R. Wallis, 2010, British journal of pharmacology.

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

A. Camm, R. Wallis, T. Hammond, 2003, Cardiovascular research.

A Pharmacokinetic‐pharmacodynamic Model for the Quantitative Prediction of Dofetilide Clinical QT Prolongation from Human Ether‐a‐go‐go‐related Gene Current Inhibition Data

D. Jonker, R. Wallis, D. Leishman, 2005, Clinical pharmacology and therapeutics.

Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society.

D J Gallacher, D J Leishman, R. Wallis, 2012, Journal of pharmacological and toxicological methods.

Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring?

Rob Wallis, Jean-Pierre Valentin, Matthew J Winter, 2008, Journal of pharmacological and toxicological methods.

Impact of study design on proarrhythmia prediction in the SCREENIT rabbit isolated heart model.

A. Mcharg, R. Wallis, D. Leishman, 2008, Journal of pharmacological and toxicological methods.

Cardiac Safety Research Consortium: can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward.

M. Malik, P. Sager, C. Garnett, 2014, American heart journal.

Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.

J. Valentin, A. Bass, L. Kinter, 2011, Journal of pharmacological and toxicological methods.

Incidence of spontaneous arrhythmias in freely moving healthy untreated Sprague-Dawley rats.

E. Troncy, S. Authier, A. Easter, 2019, Journal of pharmacological and toxicological methods.

Development and validation of a mechanism-based PK/PD model for the in vitro-in vivo prediction of QT prolongation by dofetilide

D. Jonker, R. Wallis, D. Leishman, 1998 .

The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.

H. Geys, N. McMahon, M. Deurinck, 2014, Toxicological sciences : an official journal of the Society of Toxicology.

A framework to assess the translation of safety pharmacology data to humans.

Rob Wallis, Jean-Pierre Valentin, Lorna Ewart, 2009, Journal of pharmacological and toxicological methods.

Predicting the emetic liability of novel chemical entities: a comparative study

Nathalie Percie du Sert, P. Andrews, R. Wallis, 2012, British journal of pharmacology.

The cardiac work-loop technique: An in vitro model for identifying and profiling drug-induced changes in inotropy using rat papillary muscles

R. James, R. Wallis, H. Maddock, 2020, Scientific Reports.

Predictivity of in vitro non-clinical cardiac contractility assays for inotropic effects in humans--A literature search.

R. Wallis, H. Maddock, M. Gharanei, 2015, Journal of pharmacological and toxicological methods.

A potential algorithm for predicting drug-induced nausea in man

J. Valentin, R. Wallis, W. Redfern, 2011 .

CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.

David G Strauss, Rob Wallis, Charles Benson, 2018, Journal of pharmacological and toxicological methods.

Prospects for reducing and refining the use of dogs in the regulatory toxicity testing of pharmaceuticals

G. Betton, D. Straughan, R. Combes, 2000, Human & experimental toxicology.

Evaluating Associations between Non-Clinical Cardiovascular Functional Endpoints and Repeat-Dose Cardiovascular Toxicity in the Beagle Dog: A Cross-Company Initiative.

P. Clements, D. Watson, N. McMahon, 2020, Toxicological sciences : an official journal of the Society of Toxicology.

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

W Suter, M Pirmohamed, M. Pirmohamed, 2011, British journal of pharmacology.

The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.

H. Geys, N. McMahon, M. Deurinck, 2014, Toxicological sciences : an official journal of the Society of Toxicology.